

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Qianhai Health Holdings Limited**

**前海健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 911)**

- (1) REDESIGNATION OF A DIRECTOR,  
(2) RESIGNATION OF AN EXECUTIVE DIRECTOR,  
(3) CHANGE IN COMPOSITION OF COMMITTEE MEMBERS  
AND  
(4) NON-COMPLIANCE WITH LISTING RULES**

### **REDESIGNATION OF A DIRECTOR**

The Board is pleased to announce that Mr. Yuen Chee Lap Carl has been redesignated from independent non-executive Director to executive Director and ceased to be the chairman of the Audit Committee, with effective from 23 August 2024.

### **RESIGNATION OF AN EXECUTIVE DIRECTOR**

The Board further announces that Mr. Chen Li Kuang has tendered his resignation as an executive Director with effect from 21 September 2024 due to his intention to pursue with his other commitments.

The Board announces that Mr. Chen Li Kuang shall be ceased to be the member of the Remuneration Committee and Mr. Leung Chun Tung has been appointed as a member of the Remuneration Committee, both with effect from 23 August 2024.

## REDESIGNATION OF A DIRECTOR

The Board (the “**Board**”) of directors (“**Directors**”) of Qianhai Health Holdings Limited (the “**Company**”) announces that Mr. Yuen Chee Lap Carl (“**Mr. Yuen**”) has been redesignated from independent non-executive Director to an executive Director with effect from 23 August 2024.

### **Mr. Yuen Chee Lap Carl**

Mr. Yuen Chee Lap Carl was appointed as an independent non-executive Director on 29 February 2016. Mr. Yuen graduated from the University of Houston, U.S. He attained a bachelor’s degree and a master’s degree in business administration in 1997 and 1998 respectively. He has rich experience in finance and accounting in Hong Kong and the United States. Mr. Yuen commenced his career in the United States and served as chief accountant and managerial position in several companies between 1998 and 2003. In 2004, Mr. Yuen joined Courage Investment Group Limited (stock code: 1145), a company listed on the Main Board of the Stock Exchange and the Singapore Exchange Securities Trading Limited and served as various positions during his tenure, including financial controller, chief executive officer and chief operating officer, until May 2024. Mr. Yuen was responsible for the company’s overall operations, and was in charge of the company’s finance and accounting control as well as the company’s reporting, SGX-ST and Stock Exchange compliance. Mr. Yuen is currently a member of the Hong Kong Institute of Directors and the Association of Hong Kong Accountants

In respect of the redesignation, Mr. Yuen has entered into a service contract with the Company, pursuant to which he was appointed as an executive Director for a term of three years commencing from 23 August 2024 unless terminated by not less than three months’ notice in writing served by either party on the other and is subject to retirement by rotation and re-election and other related provisions as stipulated in the articles of association of the Company. Pursuant to the service contract, Mr. Yuen shall be entitled to a remuneration package with value equivalent to HK\$1,200,000 per annum and a discretionary bonus, which was determined with reference to his duties and responsibilities with the Company and the prevailing market conditions, and shall be reviewed by the remuneration committee of the Company from time to time.

Save as disclosed herein and as at the date of this announcement, Mr. Yuen (i) does not have, and is not deemed to have, any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined under the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) of the Company; (iii) did not hold any directorship in the last three years preceding the date of this announcement in any public

companies the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) holds any other positions with the Company and its subsidiaries.

Save as disclosed above, there is no further information required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules and there is no other matter relating to the re-designation of Mr. Yuen that needs to be brought to the attention of the Stock Exchange or the Shareholders.

## **RESIGNATION OF AN EXECUTIVE DIRECTOR**

The Board announces that Mr. Chen Li Kuang (“**Mr. Chen**”) has tendered his resignation as an executive Director, with effect from 21 September 2024 due to his intention to pursue with his other commitments.

Mr. Chen confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to express its appreciation to Mr. Chen for his contributions to the Company during his tenure of services in the Company.

## **CHANGE IN COMPOSITION OF COMMITTEE MEMBERS**

The Board announces that, with effect from 23 August 2024:

- (1) Mr. Yuen has ceased to be the chairman of the audit committee of the Company (the “**Audit Committee**”);
- (2) Mr. Chen has ceased to be a member of the remuneration committee of the Company (the “**Remuneration Committee**”); and
- (3) Mr. Leung Chun Tung, our independent non-executive Director, has been appointed as a member of the Remuneration Committee.

## **NON-COMPLIANCE WITH RULES 3.10(1) AND (2), 3.10A AND 3.21 OF LISTING RULES \**

Following the redesignation of Mr. Yuen, the Company is not in compliance with (i) Rule 3.10(1) of Listing Rules, which stipulates that the Board shall comprise at least three independent non-executive directors; (ii) Rule 3.10(2) of Listing Rules, which stipulates that at least one of the independent non-executive directors must have appropriate professional qualifications or accounting or related financial management expertise; (iii) Rule 3.10A of Listing Rules, which stipulates that the number of independent nonexecutive directors shall represent at least one-third of the board; and (iv) Rule 3.21 of Listing Rules, which stipulates that the audit committee shall comprise at least three members, that at least one of whom is an independent non-executive director with appropriate professional qualifications or accounting or related financial management expertise as required under Rule 3.10(2) of Listing Rules and that the audit committee must be chaired by an independent non-executive director.

The Company will make its best endeavours to identify suitable candidates to fill the vacancies of the independent non-executive directors and the chairman of the Audit Committee as soon as possible within three months from the date of redesignation of Mr. Yuen pursuant to Rule 3.11 of the Listing Rules.

The Company will make further announcement as and when appropriate.

By order of the Board  
**Qianahi Health Holdings Limited**  
**Mr. Huang Zhiqun**  
Chairman

Hong Kong, 23 August 2024

*As at the date of this announcement, the non-executive Directors are Mr. Huang Zhiqun, Mr. Lim Tzea, Mr. Chen Kaiben and Mr. Chen Qi; the executive Directors are Mr. Chen Li Kuang and Mr. Yuen Chee Lap Carl and the independent non-executive Directors are Mr. Li Wei and Mr. Leung Chun Tung.*